 |
0 Diseases |  |
137 Trials |
|
137 Trials |  |
5343 News |  |
| «12...4567891011121314...9091» |
- || Review, Journal: COVID-19 positive woman presented with major fetal congenital anomalies: A case report with literature review. (Pubmed Central) - Sep 10, 2024
The impact of COVID-19 exposure on neonatal outcomes has not yet been fully evaluated; in this article, we aim to find if COVID-19 exposure is linked to congenital anomalies. Further research is needed to ascertain neonatal outcomes.
- | Journal: Drug Resistance in Biofilm and Planktonic Cells of Achromobacter spp., Burkholderia spp., and Stenotrophomonas maltophilia Clinical Isolates. (Pubmed Central) - Sep 9, 2024
Drug resistance increased due to biofilm production for some antibiotics, particularly ceftazidime and trimethoprim-sulfamethoxazole for all three pathogens, chloramphenicol for S. maltophilia and Burkholderia, and levofloxacin for Burkholderia. Some antibiotics could be used for the treatment of biofilm-associated infections in our population, such as levofloxacin for S. maltophilia, minocycline and meropenem for Burkholderia, and meropenem for Achromobacter.
- | Gatiflox (gatifloxacin) / Orient Europharma
Journal: Comparison of Mutant Prevention Concentrations of Fluoroquinolones Against ESBL-Positive and ESBL-Negative Klebsiella pneumoniae Isolates from Orthopedic Patients. (Pubmed Central) - Sep 9, 2024
Some antibiotics could be used for the treatment of biofilm-associated infections in our population, such as levofloxacin for S. maltophilia, minocycline and meropenem for Burkholderia, and meropenem for Achromobacter. The MPC90 values of 55 isolates of ESBL-positive K. pneumoniae against 4 fluoroquinolones were 32
- || Voquezna (vonoprazan) / Takeda, Phathom Pharma
Clinical, Journal: Vonoprazan Dual or Triple Therapy Versus Bismuth-Quadruple Therapy as First-Line Therapy for Helicobacter pylori Infection: A Three-Arm, Randomized Clinical Trial. (Pubmed Central) - Sep 8, 2024
VA-dual and VA-triple therapies are highly effective and noninferior to bismuth-quadruple therapy in Southern China. Given the lower adverse effects and fewer antibiotic use, VA-dual therapy is the preferred first-line treatment for HP infection.
- | Journal: High Carriage of tetA, sul1, sul2 and bla TEM Resistance Genes among the Multidrug-resistant Uropathogenic Escherichia coli (UPEC) Strains from Malaysian Patients. (Pubmed Central) - Sep 5, 2024
In contrast, low resistance rates were observed among minocycline (1/60; 1.7%) and imipenem (0/60; 0.0%)...The patient's age and gender were not the risk factors for the carriage of the resistance genes. Our findings identified the common resistance genes carried by the antimicrobial resistant UPEC isolates and provide valuable insights into developing the best antibiotic prescription regime to treat UTIs in our local scene.
- || levofloxacin / Generic mfg.
Clinical, Journal: Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication of Helicobacter pylori: a randomized, double-blind, placebo-controlled trial. (Pubmed Central) - Sep 5, 2024
Our findings identified the common resistance genes carried by the antimicrobial resistant UPEC isolates and provide valuable insights into developing the best antibiotic prescription regime to treat UTIs in our local scene. pylori-positive patients were randomized to receive levofloxacin-based bismuth quadruple therapy combined either probiotic LRa05 or a placebo for two weeks, followed by LRa05 (1
- ceftazidime / Generic mfg.
Evaluation of inhaled ceftazidime in people with CF () - Sep 4, 2024 - Abstract #NACFC2024NACFC_1119;
It was often used in combination with other inhaled abx or as an alternative because of intolerability to previous inhaled abx. There were no notable changes in lung function and no worsening of exacerbations or hospitalizations.
- levofloxacin / Generic mfg.
Levofloxacin-incorporated extracellular matrix nanoparticles for pulmonary cystic fibrosis infections () - Sep 4, 2024 - Abstract #NACFC2024NACFC_905;
The results show that the hybrid nanoparticles may be an effective therapy for CF bacterial infections that are capable of surpassing the mucus barrier. Further studies will look to include more physiologically relevant models specific to humans and in vivo rodent models to ensure application feasibility.
- Emblaveo (aztreonam/avibactam) / Pfizer, AbbVie, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Membrane-remodeling antimicrobials with activity against Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and Burkholderia cenocepacia complex () - Sep 4, 2024 - Abstract #NACFC2024NACFC_838;
Activity against Bcc and B. gladioli is particularly interesting given that Burkholderia is intrinsically resistant to many membrane-active antimicrobials. This provides evidence for the differentiation of ACE's membrane-remodeling mechanism, even compared with other agents that target the membrane.
- Evaluation of the ETEST gradient diffusion method for antimicrobial susceptibility testing of the Burkholderia cepacia complex () - Sep 4, 2024 - Abstract #NACFC2024NACFC_824;
When comparing ETEST with BMD, levofloxacin met all acceptance criteria, whereas ceftazidime, meropenem, minocycline, and trimethoprim-sulfamethoxazole had unacceptable very major, major, and minor error rates. For most drugs, ETEST for BCC had poorer performance than reference BMD and may not be an acceptable substitute for disk diffusion.
- ciprofloxacin oral / Generic mfg., levofloxacin / Generic mfg.
Normobaric oxygen therapy augments killing of slow-growing Pseudomonas aeruginosa by quinolones () - Sep 4, 2024 - Abstract #NACFC2024NACFC_804;
Our findings underscore the importance of quantitative sputum analysis in understanding the dynamics of chronic P. aeruginosa infections. Direct measurement of oxygen consumption in sputum samples can be considered for obtaining proof-of-concept for the advantageous use of adjuvant intermittent NBOT in PwCF.
- || Rituxan (rituximab) / Roche
Review, Journal: Mycoplasma hominis as Cause of Extragenital Infection in Patients with Hypogammaglobulinemia: Report of 2 Cases and Literature Review. (Pubmed Central) - Sep 4, 2024
Direct measurement of oxygen consumption in sputum samples can be considered for obtaining proof-of-concept for the advantageous use of adjuvant intermittent NBOT in PwCF. Patient 1 was a 61-year-old woman with diffuse large B-cell lymphoma who, after rituximab-containing chemotherapy and CAR-T therapy, developed M. hominis spondylodiscitis...Antibiotic therapy with levofloxacin and doxycycline for 10
- Risk Factors for Infections after Urological Procedures among Patients with Negative Urine Culture Screening (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3347;
- Mycobacterium Tuberculosis Liver Abscess in Kidney Transplant Recipients (Virtual) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3323;
- The Deadly Raise of NTM : An Observational Study on Clinical profile and Outcome Of NTM Disease (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3310;
- Baxdela (delafloxacin) / Menarini, Melinta Therap
Intracellular Activity of Delafloxacin Against Small Colony Variant Staphylococcus aureus (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3297;
- Propensity-Matched Comparison of Early vs. Late Antibiotic Therapy in Stenotrophomonas maltophilia Pneumonia: A Five-Hospital Study (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3283;
- imipenem/relebactam / Merck (MSD)
Susceptibility of Clinical Non-Morganellaceae Enterobacterales Isolates from Bloodstream and Respiratory Tract Infections to Imipenem/Relebactam and Comparators: SMART United States 2020-2022 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3255;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Activity of Ceftolozane/Tazobactam, Imipenem/Relebactam and Comparators Against Clinical MDR and DTR non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa Stratified by Patient Age and Hospital Ward: SMART United States 2020-2022 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3237;
- Cedax (ceftibuten dihydrate) / Currax
In Vitro Activity of Ceftibuten-Avibactam and Comparator Agents Against Enterobacterales Collected Globally as Part of the ATLAS Surveillance Program, 2022 by Region (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3231;
- Incidence and Microbiology of Postoperative Pleural Space Infections among Lung Transplant Recipients (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3147;
- Comparative efficacy of antibiotic regimens against Ureaplasma species with varying antibiotic resistance profiles in a mouse model of lung infection (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2961;
- MBI-CLABSI Cluster in Pediatric Oncology Patients with Hematologic Malignancies Introduces New Barrier in Fluoroquinolone Prophylaxis (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2718;
- Cedax (ceftibuten dihydrate) / Currax
In Vitro Potency of Ceftibuten-Avibactam (CTB-AVI) and Comparators against Extended-Spectrum Beta-Lactamase (ESBL)-like Enterobacterales from Outpatient Centers and Nursing Homes in the United States (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2630;
- Emblaveo (aztreonam/avibactam) / Pfizer, AbbVie
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against a Large Collection of Stenotrophomonas maltophilia Isolates Collected in United States Medical Centers (2019-2023) (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2623;
- Fetroja (cefiderocol) / Shionogi
Activity of Cefiderocol and Comparator Agents Against Global Isolates of Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2620;
- Emblaveo (aztreonam/avibactam) / Pfizer, AbbVie
Antimicrobial Activity of Aztreonam-Avibactam and Other ?-Lactamase Inhibitor Combinations Tested against Enterobacterales Isolates from Pediatric Patients from United States Medical Centers (2019 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2589;
- gepotidacin (GSK2140944) / GSK
In vitro Activity of Gepotidacin and Comparator Agents against a Collection of K. pneumoniae Urine Isolates from the United States During 2019-2022 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2566;
- gepotidacin (GSK2140944) / GSK
In vitro Activity of Gepotidacin against Klebsiella pneumoniae, Including Molecularly Characterized Fluoroquinolone not Susceptible Subsets Causing Urinary Tract Infections in the United States (2019-2022) (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2563;
- Jakafi (ruxolitinib) / Incyte
Painless progressive rash in a patient on ruxolitinib (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2461;
- UnLEISHing a Fever in an East African Man (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2460;
- A heart transplant recipient with one month history of night sweats, malaise, and back pain (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2441;
- A Tale of Two (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2437;
- Risk Factors for 90-day Mortality Among Patients With Stenotrophomonas maltophilia Infection: A Retrospective Multicenter study (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2060;
- Evaluating the Association of Unnecessary Antibiotic Use with Hospital-Onset Clostridioides difficile Infection at a New York City Hospital (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1963;
- Detecting Evidence for Bystander Selection by Comparing Trends in Antibiotic Resistance among Infection Causing Bacteria in a Large Global AMR Database (Virtual) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1899;
- Development of a Local Multidrug-Resistant Gram-Negative Antibiogram (Virtual) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1780;
- Reverse Blot Hybridization Assay for Simultaneous Multi-drug Resistance Detection of Helicobacter pylori (Virtual) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1746;
- Nuzyra (omadacycline) / Paratek
Safety of Omadacycline Versus Standard-of-Care Oral Antibiotic Treatment for Bone and Joint Infections: Interim Results from an Open-Label, Non- Inferiority, Randomized Controlled Trial (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1478;
- The First-in-Class Anti-Staphylococcal Antibiotic Afabicin Desphosphono is Not Associated With Clostridioides difficile Infection in an in vitro Human Gut Model (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1407;
- Identifying Hospital Antimicrobial Usage Trends Using Wastewater Based Surveillance (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1299;
- Antibiotic De-Escalation in Neutropenic Fever (Virtual) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1259;
- Impact of a Pharmacist-driven Antipseudomonal Antibiotic Time-out (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1239;
- Impact of Antibiotic Usage on Antimicrobial Resistance Rates among Gram-Negatives at a COVID-Care Facility (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1205;
- Differences in Guideline-Concordant Antibiotic Prescribing Based on Age, Sex, Race, and Ethnicity for the Management of Inpatients with Community-Acquired Bacterial Pneumonia (CABP) due to Pseudomonas aeruginosa: a Retrospective Cohort Analysis of the All of Us Database. (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1204;
- Determining Appropriateness of Pneumonia Treatment in Long-Term Care Facilities Pilot Project (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1197;
- Benchmarking Clinical Outcomes by Antimicrobial Spectrum in Patients with Community-Acquired Pneumonia (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1178;
- Effect of Penicillin Allergy on Common Urinary Tract Pathogens within a Community Health-System Antibiogram (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1150;
- Hematology-Oncology Unit-Specific Antibiogram: A Decade of Experience at a Large Academic Medical Center (Virtual) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1149;
- Shifting Susceptibilities and Clinical Outcomes of Oncology Patients with Streptococcus mitis/oralis Bacteremia (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1147;